Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05118750 · ClinicalTrials.gov registry record · Phase 2
ALTO-300 in Depression
A Phase 2 study, sponsored by Alto Neuroscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
NCT05118750: Completed Phase 2 study, sponsored by Alto Neuroscience.
NCT05118750 is a Phase 2 study that has completed, run by Alto Neuroscience. The registered enrollment target is 91 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05118750, a Phase 2 study, has completed, sponsored by Alto Neuroscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
Primary Outcome
The Montgomery-Åsberg Depression Rating Scale (MADRS) measures the severity of depression where smaller scores indicate less depression and higher scores suggest more severe depression. Possible scores for this 10 item version range from 0 to 60. The change from baseline to the end of the study is the primary outcome.
Interventions
- DRUG ALTO-300 oral (PO) tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 2 |
What the finished NCT05118750 record still lists
NCT05118750 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which ALTO-300 oral (PO) tablet is the first listed.
NCT05118750 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05118750 about?
NCT05118750 is a clinical study titled "ALTO-300 in Depression". The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
What is the current status of trial NCT05118750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2021-12-13. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05118750?
The interventions under investigation include: ALTO-300 oral (PO) tablet (DRUG).
Who is sponsoring clinical trial NCT05118750?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05118750's enrollment target sits among peer trials
91 771st of 2000 higher than 1,229 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI